OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Jeffrey A. Sparks, Zachary S. Wallace, Andrea M. Seet, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 9, pp. 1137-1146
Open Access | Times Cited: 212
Jeffrey A. Sparks, Zachary S. Wallace, Andrea M. Seet, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 9, pp. 1137-1146
Open Access | Times Cited: 212
Showing 1-25 of 212 citing articles:
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
Rebecca Grainger, Alfred H.J. Kim, Richard Conway, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 4, pp. 191-204
Open Access | Times Cited: 159
Rebecca Grainger, Alfred H.J. Kim, Richard Conway, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 4, pp. 191-204
Open Access | Times Cited: 159
Richard Conway, Alyssa Grimshaw, Maximilian F. Konig, et al.
Arthritis & Rheumatology (2021) Vol. 74, Iss. 5, pp. 766-775
Open Access | Times Cited: 158
Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study
Natacha Madelon, Kim Lauper, Gautier Bréville, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e1037-e1045
Open Access | Times Cited: 107
Natacha Madelon, Kim Lauper, Gautier Bréville, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e1037-e1045
Open Access | Times Cited: 107
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
Brian MacKenna, Nicholas A. Kennedy, Amir Mehrkar, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 7, pp. e490-e506
Open Access | Times Cited: 92
Brian MacKenna, Nicholas A. Kennedy, Amir Mehrkar, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 7, pp. e490-e506
Open Access | Times Cited: 92
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance
Manuel F. Ugarte‐Gil, Graciela S. Alarcón, Zara Izadi, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 7, pp. 970-978
Open Access | Times Cited: 79
Manuel F. Ugarte‐Gil, Graciela S. Alarcón, Zara Izadi, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 7, pp. 970-978
Open Access | Times Cited: 79
Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy
Gian Marco Leone, Katia Mangano, Maria Cristina Petralia, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 4, pp. 1630-1630
Open Access | Times Cited: 73
Gian Marco Leone, Katia Mangano, Maria Cristina Petralia, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 4, pp. 1630-1630
Open Access | Times Cited: 73
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
Michael Bonelli, Andreas Kerschbaumer, Kastriot Kastrati, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 2, pp. 139-160
Open Access | Times Cited: 45
Michael Bonelli, Andreas Kerschbaumer, Kastriot Kastrati, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 2, pp. 139-160
Open Access | Times Cited: 45
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study
Grace Qian, Xiaosong Wang, Naomi J. Patel, et al.
The Lancet Rheumatology (2023) Vol. 5, Iss. 3, pp. e139-e150
Open Access | Times Cited: 42
Grace Qian, Xiaosong Wang, Naomi J. Patel, et al.
The Lancet Rheumatology (2023) Vol. 5, Iss. 3, pp. e139-e150
Open Access | Times Cited: 42
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study
Md Yuzaiful Md Yusof, Jack Arnold, Benazir Saleem, et al.
The Lancet Rheumatology (2023) Vol. 5, Iss. 2, pp. e88-e98
Open Access | Times Cited: 41
Md Yuzaiful Md Yusof, Jack Arnold, Benazir Saleem, et al.
The Lancet Rheumatology (2023) Vol. 5, Iss. 2, pp. e88-e98
Open Access | Times Cited: 41
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses
Filippo Fagni, David Simón, Koray Taşçılar, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 10, pp. e724-e736
Open Access | Times Cited: 94
Filippo Fagni, David Simón, Koray Taşçılar, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 10, pp. e724-e736
Open Access | Times Cited: 94
Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States
Rahul Raiker, Charles DeYoung, Haig Pakhchanian, et al.
Seminars in Arthritis and Rheumatism (2021) Vol. 51, Iss. 5, pp. 1057-1066
Open Access | Times Cited: 73
Rahul Raiker, Charles DeYoung, Haig Pakhchanian, et al.
Seminars in Arthritis and Rheumatism (2021) Vol. 51, Iss. 5, pp. 1057-1066
Open Access | Times Cited: 73
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative
Kathleen M. Andersen, Benjamin Bates, Emaan Rashidi, et al.
The Lancet Rheumatology (2021) Vol. 4, Iss. 1, pp. e33-e41
Open Access | Times Cited: 73
Kathleen M. Andersen, Benjamin Bates, Emaan Rashidi, et al.
The Lancet Rheumatology (2021) Vol. 4, Iss. 1, pp. e33-e41
Open Access | Times Cited: 73
Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis
Jessica Widdifield, Jeffrey C. Kwong, Simon Chen, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 6, pp. e430-e440
Open Access | Times Cited: 38
Jessica Widdifield, Jeffrey C. Kwong, Simon Chen, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 6, pp. e430-e440
Open Access | Times Cited: 38
Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C)
Namrata Singh, Vithal Madhira, Chen Hu, et al.
Seminars in Arthritis and Rheumatism (2022) Vol. 58, pp. 152149-152149
Open Access | Times Cited: 38
Namrata Singh, Vithal Madhira, Chen Hu, et al.
Seminars in Arthritis and Rheumatism (2022) Vol. 58, pp. 152149-152149
Open Access | Times Cited: 38
Clinical course and management of COVID-19 in the era of widespread population immunity
Eric A. Meyerowitz, Jake Scott, Aaron Richterman, et al.
Nature Reviews Microbiology (2023) Vol. 22, Iss. 2, pp. 75-88
Closed Access | Times Cited: 33
Eric A. Meyerowitz, Jake Scott, Aaron Richterman, et al.
Nature Reviews Microbiology (2023) Vol. 22, Iss. 2, pp. 75-88
Closed Access | Times Cited: 33
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
Roy Fleischmann, Jeffrey R. Curtis, Christina Charles‐Schoeman, et al.
Annals of the Rheumatic Diseases (2023), pp. ard-223916
Open Access | Times Cited: 30
Roy Fleischmann, Jeffrey R. Curtis, Christina Charles‐Schoeman, et al.
Annals of the Rheumatic Diseases (2023), pp. ard-223916
Open Access | Times Cited: 30
Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis
Atsushi Sakuraba, Alexander Luna, Dejan Micić
Gastroenterology (2021) Vol. 162, Iss. 1, pp. 88-108.e9
Open Access | Times Cited: 51
Atsushi Sakuraba, Alexander Luna, Dejan Micić
Gastroenterology (2021) Vol. 162, Iss. 1, pp. 88-108.e9
Open Access | Times Cited: 51
Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia
Е. Л. Насонов, А. М. Лила, Mazurov Vi, et al.
Rheumatology Science and Practice (2021) Vol. 59, Iss. 3, pp. 239-254
Open Access | Times Cited: 50
Е. Л. Насонов, А. М. Лила, Mazurov Vi, et al.
Rheumatology Science and Practice (2021) Vol. 59, Iss. 3, pp. 239-254
Open Access | Times Cited: 50
Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study
Gabriel Figueroa‐Parra, Emily Gilbert, Maria O. Valenzuela‐Almada, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 11, pp. e765-e774
Open Access | Times Cited: 36
Gabriel Figueroa‐Parra, Emily Gilbert, Maria O. Valenzuela‐Almada, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 11, pp. e765-e774
Open Access | Times Cited: 36
Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study
Naomi J. Patel, Xiaosong Wang, Xiaoqing Fu, et al.
Seminars in Arthritis and Rheumatism (2022) Vol. 58, pp. 152108-152108
Open Access | Times Cited: 36
Naomi J. Patel, Xiaosong Wang, Xiaoqing Fu, et al.
Seminars in Arthritis and Rheumatism (2022) Vol. 58, pp. 152108-152108
Open Access | Times Cited: 36
CD4+T-Cell Dysfunction in Severe COVID-19 Disease Is Tumor Necrosis Factor-α/Tumor Necrosis Factor Receptor 1–Dependent
Iulia Popescu, Mark E. Snyder, Carlo J. Iasella, et al.
American Journal of Respiratory and Critical Care Medicine (2022) Vol. 205, Iss. 12, pp. 1403-1418
Open Access | Times Cited: 32
Iulia Popescu, Mark E. Snyder, Carlo J. Iasella, et al.
American Journal of Respiratory and Critical Care Medicine (2022) Vol. 205, Iss. 12, pp. 1403-1418
Open Access | Times Cited: 32
Breakthrough SARS – CoV ‐2 Infections in Patients With Immune‐Mediated Disease Undergoing B Cell–Depleting Therapy: A Retrospective Cohort Analysis
Cassandra Calabrese, E. Kirchner, M. Elaine Husni, et al.
Arthritis & Rheumatology (2022) Vol. 74, Iss. 12, pp. 1906-1915
Open Access | Times Cited: 31
Cassandra Calabrese, E. Kirchner, M. Elaine Husni, et al.
Arthritis & Rheumatology (2022) Vol. 74, Iss. 12, pp. 1906-1915
Open Access | Times Cited: 31
New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics
Satoshi Ebata, Asako Yoshizaki‐Ogawa, Shinichi Sato, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 15, pp. 4631-4631
Open Access | Times Cited: 29
Satoshi Ebata, Asako Yoshizaki‐Ogawa, Shinichi Sato, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 15, pp. 4631-4631
Open Access | Times Cited: 29
Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab
Tejas S. Athni, Sara Barmettler
Annals of Allergy Asthma & Immunology (2023) Vol. 130, Iss. 6, pp. 699-712
Open Access | Times Cited: 18
Tejas S. Athni, Sara Barmettler
Annals of Allergy Asthma & Immunology (2023) Vol. 130, Iss. 6, pp. 699-712
Open Access | Times Cited: 18
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Pedro Machado, Martin Schäfer, Satveer K. Mahil, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 5, pp. 698-709
Open Access | Times Cited: 15
Pedro Machado, Martin Schäfer, Satveer K. Mahil, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 5, pp. 698-709
Open Access | Times Cited: 15
